INDICATIONS
Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA approved test. 

DOSAGE AND ADMINISTRATION
Patient Selection
Select patients for treatment with Capmatinib based on the presence of a mutation that leads to MET exon 14 skipping in tumor or plasma specimens. If a mutation that leads to MET exon 14 skipping is not detected in a plasma specimen, test tumor tissue if feasible. 

Recommended Dose
The recommended dosage of Capmatinib is 400 mg orally twice daily with or without food.

Swallow Capmatinib tablets whole. Do not break, crush or chew the tablets.

If a patient misses or vomits a dose, instruct the patient not to make up the dose, but to take the next dose at its scheduled time.

Dosage Modifications for Adverse Reactions
The recommended dose reductions for the management of adverse reactions are listed in Table 1.

 Table 1: Recommended Capmatinib Dose Reductions for Adverse Reactions

Permanently discontinue Capmatinib in patients who are unable to tolerate 200 mg orally twice daily.

FIND A PRODUCT